Live combined bacillus subtilis and enterococcus faecium ameliorate murine experimental colitis by immunosuppression

International Journal of Inflammation

Volumn 2014, Issue , 2014, Pages

  Chen, S ^a   Fu, Y ^a   Liu, L L ^b   Gao, W ^b   Liu, Y L ^b   Fei, S H ^a   Tan, Y ^a   Zou, K F ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MEDILAC S; MESSENGER RNA; MYELOPEROXIDASE; PROBIOTIC AGENT; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACILLUS SUBTILIS; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DOWN REGULATION; ENTEROCOCCUS FAECIUM; ENZYME ACTIVITY; EOSINOPHIL; EXPERIMENTAL RAT; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; LYMPHOCYTE; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL; UPREGULATION;

EID: 84934946346     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2014/878054     Document Type: Article

References (24)

1. T. Kucharzik, C. Maaser, A. Lügering et al., "Recent underst and ing of IBDpathogenesis: implications for future therapies, " Inflammatory BowelDiseases, vol. 12, no. 11, pp. 1068-1083, 2006.
2. C. Schmidt and A. Stallmach, "Etiology and pathogenesis of inflammatory bowel disease, " Minerva Gastroenterologica e Dietologica, vol. 51, no. 2, pp. 127-145, 2005.
3. K. O. Arseneau, H. Tamagawa, T. T. Pizarro, and F. Cominelli, "Innate and adaptive immune responses related to IBD pathogenesis, " CurrentGastroenterology Reports, vol. 9, no.6, pp. 508-512, 2007.
4. T. T. MacDonald, A. Vossenkaemper, M. Fantini, and G. Monteleone, "Reprogramming the immune system in IBD, " Digestive Diseases, vol. 30, no. 4, pp. 392-395, 2012.
5. A. B. Pithadia and S. Jain, "Treatment of inflammatory bowel disease (IBD), " Pharmacological Reports, vol. 63, no. 3, pp. 629-642, 2011.
6. D. Jonkers, J. Penders, A. Masclee, and M. Pierik, "Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients, " Drugs, vol. 72, no. 6, pp. 803-823, 2012.
7. M. H. Floch, W. A. Walker, S. Gu and alini et al., "Recommendations for probiotic use-2008, " Journal of Clinical Gastroenterology, vol. 42, supplement 2, no. 2, pp. S104-S108, 2008.
8. K. Isaacs and H. Herfarth, "Role of probiotic therapy in IBD, " Inflammatory Bowel Diseases, vol. 14, no. 11, pp. 1597-1605, 2008.
9. G. Hormannsperger, T. Clavel, M. Hoffmann et al., "Posttranslational inhibition of proinflammatory chemokine secretion in intestinal epithelial cells: implications for specific IBD indications, " Journal of Clinical Gastroenterology, vol. 44, no. 1, pp. S10-S15, 2010.
10. R. B. Sartor and M. Muehlbauer, "Microbial host interactions in IBD: implications for pathogenesis and therapy, " Current Gastroenterology Reports, vol. 9, no. 6, pp. 497-507, 2007.
11. R. N. Fedorak, "Underst and ing why probiotic therapies can be effective in treating IBD, " Journal of Clinical Gastroenterology, vol. 42, supplement 3, part 1, pp. S111-S115, 2008.
12. T. Hibi, H. Ogata, and A. Sakuraba, "Animal models of inflammatory bowel disease, " Journal of Gastroenterology, vol. 37, no. 6, pp. 409-417, 2002.
13. J. E. Qualls, A. M. Kaplan, N. van Rooijen, and D. A. Cohen, "Suppression of experimental colitis by intestinal mononuclear phagocytes, " Journal of Leukocyte Biology, vol. 80, no. 4, pp. 802-815, 2006.
14. K. M. Taylor and P. M. Irving, "Optimization of conventional therapy in patients with IBD, " Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 11, pp. 646-656, 2011.
15. R. N. Fedorak, "Underst and ing why probiotic therapies can be effective in treating IBD, " Journal of Clinical Gastroenterology, vol. 42, pp. S111-S115, 2008.
16. S. Lebeer, J. V and erleyden, and S. C. De Keersmaecker, "Genes and molecules of lactobacilli supporting probiotic action, " Microbiology and Molecular Biology Reviews, vol. 72, no. 4, pp. 728-764, 2008.
17. E. Cario, "Toll-like receptors in inflammatory bowel diseases: a decade later, " Inflammatory Bowel Diseases, vol. 16, no. 9, pp. 1583-1597, 2010.
18. T. Kawai and S. Akira, "Toll-like receptor downstream signaling, " Arthritis Research and Therapy, vol. 7, no. 1, pp. 12-19, 2005.
19. M. A. Anwar, S. Basith, and S. Choi, "Negative regulatory approaches to the attenuation of Toll-like receptor signaling, " Experimental and Molecular Medicine, vol. 45, no. 2, article e11, 2013.
20. S. Chen, K. Zou, T. Yang, Y. Tan, Y. Ding, and W. Qian, "Expression and significance of toll-like receptor (TLR) 2, TLR4 and TLR9 in colonic mucosa of rat model with induced colitis, " Chinese Journal of Gastroenterology, vol. 12, no. 6, pp. 339-343, 2007.
21. I. Sabroe and M. K. B. Whyte, "Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease, " Biochemical Society Transactions, vol. 35, no. 6, pp. 1492-1495, 2007.
22. K. H. G. Mills, "TLR-dependent T cell activation in autoimmunity, " Nature Reviews Immunology, vol. 11, no. 12, pp. 807-822, 2011.
23. J. Bessa and M. F. Bachmann, "T cell-dependent and -independent IgA responses: role of TLR signalling, " Immunological Investigations, vol. 39, no. 4-5, pp. 407-428, 2010.
24. A.H. Rahman, D. K. Taylor, and L. A. Turka, "The contribution of direct TLR signaling to T cell responses, " Immunologic Research, vol. 45, no. 1, pp. 25-36, 2009.